A Partnership to Enhance Drug Development Effectiveness Creating a Gateway to Clinical Breakthroughs
To be successful in drug development, CRO’s must be able to image and interpret many different tissues and pathologies with different imaging devices, see a tumor of cancer, measure its dimensions (extent of margins), then mathematically quantify changes, and reflect changes in the images with confirmed pathology at the cellular level. Imago’s Visual Intelligence™ (VI®) technology can make that possible.
IMAGO believes that the concepts and outcomes of its research will have direct benefits to Pharmaceutical and Biotech companies in conducting drug development trials. At its core Imago transforms unstructured, low-contrast, poorly differentiated data into structured, usable, visible data.
By improving trial design and incorporating visual efficacy, Imago can help reduce the number of trials that fail at later stages. The data compiled through Imago Systems’ Phase I research contract with the National Cancer Institute for Novel Diagnostic Imaging for Monitoring Tumor Response to Immunotherapy demonstrated that Imago could determine the progression or regression of tumors early in development in animal models. These observations will aid in clinical studies to determine if a specific drug is efficacious or not.
- IMAGO’S patented imaging algorithms enable the study of tissues that are difficult to sample through biopsy, such as lesions in cancer patients. Imago’s imaging may eliminate the need for a biopsy
- Allow for earlier decision-making as to the effectiveness of potential treatments in determining tumor progression or regression
- Dramatically reduced costs by spending less time analyzing images while helping reduce the probability of errors occurring during image assessment
- IMAGO’S Visual Intelligence™ (VI®) solution can reduce drug development timelines and accelerate regulatory approvals